Results 201 to 210 of about 61,480 (319)

The Role of Clinical Pharmacogenetics and Opioid Interactions in Pain Management: Current Evidence and Future Perspectives. [PDF]

Pharmaceutics
Di Salvo C, Valdiserra G, Balestrieri S, Beucci G, Paciulli G, Luculli GI, De Vita A, Fornai M, Di Paolo A, Antonioli L.   +9 more
europepmc   +1 more source

Structure-Based Inhibitor Design for Evaluation of a CYP3A4 Pharmacophore Model.

Journal of Medicinal Chemistry, 2016
P. Kaur, A. Chamberlin, T. Poulos, F. Irina, Sevrioukova   +4 more
semanticscholar   +1 more source

Role of CYP3A4 in kinase inhibitor metabolism and assessment of CYP3A4 activity

Translational Cancer Research, 2017
Gerd Mikus, Kathrin Isabelle Foerster
openaire   +1 more source

Effect of Testosterone Therapy on Cytochrome P450 3A and P‐Glycoprotein Activities Using Midazolam and Digoxin as Probe Substrates Among Transgender Adults

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 46, Issue 2, February 2026.
ABSTRACT Background Gender‐affirming testosterone therapy is one part of the standard of care for more than 1 million transgender adults in the United States. Testosterone therapy may influence the activities of drug‐metabolizing enzymes and transporters, but knowledge about its effect on the pharmacokinetics of other medications is limited.
Michiko Hunter, Rene Coig, Linda Risler, Kristen K. Patton, Radhika R. Narla, Dina N. Greene, Alson K. Burke, Elizabeth Micks, Mary F. Hebert, Lauren R. Cirrincione   +9 more
wiley   +1 more source

​Temporal proteomic profiling of iPSC-derived human liver organoids reveals optimal maturation for drug metabolism and toxicology. [PDF]

Sci Rep
Yang S, Hao J, Ooka M, Xia M.
europepmc   +1 more source

Impact of Grapefruit Consumption on Plasma Concentrations of Psychiatric Medications through CYP3A4 Inhibition [PDF]

David Valle, David J. Cox, Bruce R. Carr
openalex   +1 more source

A Fibroblast Growth Factor 21–Pregnane X Receptor Pathway Downregulates Hepatic CYP3A4 in Nonalcoholic Fatty Liver Disease [PDF]

, 2016
Sarah Woolsey, Melanie Beaton, Sara E. Mansell, Matilde Leon‐Ponte, Janice Yu, Christopher L. Pin, Paul C. Adams, Richard B. Kim, Rommel G. Tirona   +8 more
openalex   +1 more source

Gut Microbial Variations Associated With Proton Pump Inhibitor Use in the Boston Puerto Rican Health Study

Pharmacology Research &Perspectives, Volume 14, Issue 1, February 2026.
ABSTRACT Proton pump inhibitors (PPI), used to treat gastrointestinal disorders, are associated with alterations in the gut microbiome. However, this is understudied in Puerto Ricans who have unique lifestyle characteristics. Puerto Ricans, including participants of the Boston‐Puerto Rican Health Study (BPRHS), report high PPI use.
Deepika Dinesh, Xochitl C. Morgan, Hanseul Kim, Tammy M. Scott, Mahdi Garelnabi, Jong Soo Lee, Kelsey M. Mangano, Long H. Nguyen, Curtis Huttenhower, Katherine L. Tucker, Natalia Palacios   +10 more
wiley   +1 more source

Berberine and berberrubine promote the expression of CYP3A4 via enhancing the binding of nuclear receptor PXR. [PDF]

BMC Pharmacol Toxicol
Xiao GM, Lu T, Zhu D, Liu MY.
europepmc   +1 more source

薬物のBioavailabilityにおける小腸のCYP3A4およびP-糖蛋白質の寄与について　―シクロスポリンを例として―

, 1999
笠原 美枝
openalex   +2 more sources